IP Library Granted Patent US 10,195,234
Granted Patent B2
US 10,195,234 · App. 15/301,324 · Granted Feb 5, 2019

Bacteria engineered to reduce hyperphenylalaninemia

Inventors: Dean Falb (Sherborn, MA); Vincent M. Isabella (Cambridge, MA); Jonathan W. Kotula (Somerville, MA); Paul F. Miller (Salem, CT); Sarah Rowe (Somerville, MA); Yves Millet (Newton, MA)
Assignee: Synlogic Operating Company, Inc.
A61K35/74A61K35/741A61K39/02C07K14/195C07K14/245C12N9/0014C12N9/0022C12N9/88C12N15/70C12Y104/03002C12Y403/01024A61K38/00A61K2035/11Y02A50/473
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,195,234
App. No.
15/301,324
Granted
Feb 5, 2019
Kind
B2
Abstract

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.

Claims (19)

1. A bacterium for metabolizing phenylalanine comprising:

a) one or more gene(s) encoding a phenylalanine ammonia lyase (PAL), wherein the one or more gene(s) encoding the PAL is operably linked to a promoter that is not associated in nature with the one or more gene(s) encoding PAL, said promoter directly or indirectly induced under low-oxygen or anaerobic conditions; and

b) one or more gene(s) encoding a non-native phenylalanine transporter, wherein the one or more gene(s) encoding the phenylalanine transporter is operably linked to a promoter that is not associated in nature with the one or more gene(s) encoding the phenylalanine transporter, said promoter directly or indirectly induced under low-oxygen or anaerobic conditions;

wherein the bacterium expresses the gene(s) encoding PAL under conditions that induce the promoter operably linked to the gene(s) encoding PAL, and

wherein the bacterium expresses the gene(s) encoding phenylalanine transporter under conditions that induce the promoter operably linked to the gene(s) encoding the phenylalanine transporter; and wherein the bacterium is Escherichia coli strain Nissle.

2. The bacterium of claim 1 , wherein the promoter operably linked to the gene(s) encoding a PAL and the promoter operably linked to the gene(s) encoding a phenylalanine transporter are separate copies of the same promoter.

3. The bacterium of claim 1 , wherein the promoter operably linked to the gene(s) encoding a PAL and the promoter operably linked to the gene(s) encoding the phenylalanine transporter are different promoters.

4. The bacterium of claim 1 , wherein the promoter is selected from the group consisting of an FNR-responsive promoter, an ANR-responsive promoter, and a DNR-responsive promoter.

5. The bacterium of claim 1 , wherein the promoter operably linked to the gene(s) encoding a PAL and/or the promoter operably linked to the gene(s) encoding a phenylalanine transporter is directly or indirectly induced by an environmental factor that is not naturally present in a mammalian gut.

6. The bacterium of claim 1 , wherein the gene(s) encoding a phenylalanine transporter is located on a chromosome in the bacterium.

7. The bacterium of claim 1 , wherein the gene(s) encoding a phenylalanine transporter is located on a plasmid in the bacterium.

8. The bacterium of claim 1 , wherein the gene(s) encoding a PAL is located on a plasmid in the bacterium.

9. The bacterium of claim 1 , wherein the gene(s) encoding a PAL is located on a chromosome in the bacterium.

10. The bacterium of claim 1 , wherein the PAL is from Anabaena variabilis (PAL1) or from Photorhabdus luminescens (PAL3).

11. The bacterium of claim 1 , wherein the phenylalanine transporter is PheP.

12. The bacterium of claim 1 , wherein the bacterium is a probiotic bacterium.

13. The bacterium of claim 1 , wherein the bacterium is an auxotroph in a gene that is complemented when the bacterium is present in a mammalian gut.

14. The bacterium of claim 13 , wherein the bacterium is an auxotroph in diaminopimelic acid or an enzyme in the thymidine biosynthetic pathway.

15. A pharmaceutically acceptable composition comprising the bacterium of claim 1 .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ASSIGNMENT PREVIOUSLY RECORDED AT REEL: 041954 FRAME: 0915. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 20, 2023
From: FALB, DEAN; ISABELLA, VINCENT M.; KOTULA, JONATHAN W.; MILLER, PAUL F.; MILLET, YVES
To: SYNLOGIC, INC.
Reel/Frame 063117/0883 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2023
From: ROWE, SARAH
To: SYNLOGIC, INC.
Reel/Frame 062773/0234 →
MERGER AND CHANGE OF NAME Recorded Apr 15, 2018
From: SYNLOGIC, INC.; MEERKAT MERGER SUB, INC.; SYNLOGIC OPERATING COMPANY, INC.
To: SYNLOGIC OPERATING COMPANY, INC.
Reel/Frame 045544/0530 →
Continuity (3)
Provisional Application 62161137 · May 13, 2015
Provisional Application 62256052 · Nov 16, 2015
Related Publication 20170312320A1 · Nov 2, 2017
Cited By (2)
US 12,409,195 US 12,545,886